Moderna Soars Over 600% This Year, Personalized Cancer Vaccine Becomes Key Catalyst - NAI500
Moderna shares have surged more than 600% this year, with the company's personalized cancer vaccine program cited as a key catalyst, according to NAI500. The rally signals investors are treating Moderna's oncology franchise as a material growth driver rather than a side bet alongside its respiratory portfolio. With the full phase 3 INTerpath-001 data for the Merck-partnered intismeran autogene now public, the commercial narrative behind the stock's run has a concrete clinical anchor.